Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lumiracoxib (Novartis).

Changhai Ding1, Graeme Jones

  • 1Menzies Centre for Population Health Research, University of Tasmania, 17 Liverpool Street, Hobart 7000, Tasmania, Australia. chding@utas.edu.au

Idrugs : the Investigational Drugs Journal
|June 12, 2003
PubMed
Summary

Lumiracoxib, a COX-2 inhibitor, is being developed for arthritis and pain. Phase III trials were underway in late 2000 and continued through 2001.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in heterogeneity and classification of osteoarthritis.

Bone research·2026
Same author

Bidirectional Relationship and Shared Mechanisms Between Sarcopenia and Osteoporosis: An Observational Study Integrating Genomic, Proteomic, and Metabolomic Data.

Aging cell·2026
Same author

Tristetraprolin protects against osteoarthritis by restraining chondrocyte mitochondrial DNA release through post-transcriptional regulation.

Journal of orthopaedic translation·2026
Same author

Temporal Trends and Cross-Country Inequalities in the Burden of Osteoarthritis, 1990-2021: Findings From the Global Burden of Disease Study 2021.

International journal of rheumatic diseases·2026
Same author

Corrigendum to 'Vitamins D and K jointly protect against osteoarthritis via regulating OSCAR during osteoclastogenesis' [J Orthop Transl <b>52</b> (2025) 387-403].

Journal of orthopaedic translation·2026
Same author

Associations of centrally acting analgesic use with total joint arthroplasty compared to selective serotonin reuptake inhibitor among osteoarthritis patients in a large prospective cohort.

BMC medicine·2026

Area of Science:

  • Pharmacology
  • Drug Development
  • Clinical Trials

Background:

  • Lumiracoxib is a selective cyclooxygenase 2 (COX-2) inhibitor.
  • It is being developed by Novartis.
  • Potential therapeutic applications include osteoarthritis, rheumatoid arthritis, and pain management.

Purpose of the Study:

  • To evaluate the efficacy and safety of Lumiracoxib.
  • To assess its potential as a treatment for inflammatory conditions and pain.

Main Methods:

  • Initiation of Phase III clinical trials.
  • Ongoing clinical evaluation through December 2001.

Main Results:

  • Phase III trials were initiated by late December 2000.
  • Trials were actively ongoing as of December 2001, indicating continued development and data collection.

Conclusions:

  • Lumiracoxib development for arthritis and pain was progressing through advanced clinical trials.
  • Further data from ongoing Phase III studies are expected to determine its therapeutic viability.

Related Experiment Videos